Scholarlink

<p><i>MET</i> proto-oncogene amplification (<i>MET</i>amp) is associated with poor prognosis in gastric or gastroesophageal junction (G/GEJ) cancer. Currently, effective targeted therapies for G/GEJ cancer harboring <i>MET</i>amp remain unavailable, and clinical evidence supporting the use of MET inhibitors in this disease population is limited. Here we report the results of a phase 2 study of savolitinib, an oral MET inhibitor, in patients with <i>MET</i>amp G/GEJ cancer. This open-label, multicenter, phase 2 trial in China comprised an exploratory phase and a pivotal phase. Patients with <i>MET</i>amp (gene copy number ≥10 for pivotal phase), locally advanced or metastatic G/GEJ cancer that had progressed following ≥1 (≥2 for pivotal phase) prior lines of systemic therapy received savolitinib orally. The primary endpoint was objective response rate (ORR) by independent review committee in the pivotal phase. In total, 110 patients were enrolled and received savolitinib, including 45 in the exploratory phase and 65 in the pivotal phase. Independent review committee-assessed ORR was 32.3% (95% confidence interval 21.2–45.1%) in the pivotal phase, which met the predefined efficacy threshold (lower limit of 95% confidence interval of ORR ≥15%). Among all patients enrolled (<i>n</i> = 110), grade ≥3 treatment-related adverse events were reported in 38 patients (34.5%); one (0.9%) treatment-related death occurred. Savolitinib monotherapy showed encouraging antitumor activities and a tolerable safety profile in heavily treated, later-line <i>MET</i>amp G/GEJ cancers, supporting further investigation in randomized controlled trials. ClinicalTrials.gov identifier: <a href="https://clinicaltrials.gov/study/NCT04923932">NCT04923932</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

  • 期刊论文

  • 发表日期：

    2026年6月1日

查看全文
  • Zhi Peng,
  • Tianshu Liu,
  • Hua Wang,
  • Jufeng Wang,
  • Hongli Liu,
  • Feng Ye,
  • Enxiao Li,
  • Jun Zhang,
  • Baorui Liu,
  • Rongbo Lin,
  • Aiping Zhou,
  • Zhenyang Liu,
  • Huiting Xu,
  • Qiong Wang,
  • Zuoxing Niu,
  • Ying Yuan,
  • Yanru Qin,
  • Xiujuan Qu,
  • Yuxian Bai,
  • Ning Liu,
  • Hailong Liu,
  • Chunmei Bai,
  • Yueyin Pan,
  • Shubin Wang,
  • Tao Wu,
  • Qinghua Pan,
  • Diansheng Zhong,
  • Hongxia Lu,
  • Junye Wang,
  • Zhiyu Wang,
  • Ting Deng,
  • Hongfeng Gou,
  • Xiwen Huang,
  • Sisi Fu,
  • Puhan Lu,
  • Jie Yu,
  • Mengyang Hong,
  • Qian Xu,
  • Linfang Wang,
  • Yongxin Ren,
  • Songhua Fan,
  • Lin Shen,
  • Yan Yang,
  • Yongshun Chen,
  • Dianbao Zhang,
  • Lixin Wan,
  • Huiqing Zhang,
  • Ping Chen,
  • Jianming Xu,
  • Tienan Yi,
  • Zhixiang Zhuang,
  • Hongming Pan,
  • Mingjun Zhang,
  • Wei Li,
  • Yushuang Luo,
  • Kangsheng Gu,
  • Fang Wen,
  • Jinsheng Wu,
  • Kejun Nan,
  • Yawen Gao,
  • Guifang Yu,
  • Zhan Lin,
  • Zhongxian Zheng

摘要

MET proto-oncogene amplification (METamp) is associated with poor prognosis in gastric or gastroesophageal junction (G/GEJ) cancer. Currently, effective targeted therapies for G/GEJ cancer harboring METamp remain unavailable, and clinical evidence supporting the use of MET inhibitors in this disease population is limited. Here we report the results of a phase 2 study of savolitinib, an oral MET inhibitor, in patients with METamp G/GEJ cancer. This open-label, multicenter, phase 2 trial in China comprised an exploratory phase and a pivotal phase. Patients with METamp (gene copy number ≥10 for pivotal phase), locally advanced or metastatic G/GEJ cancer that had progressed following ≥1 (≥2 for pivotal phase) prior lines of systemic therapy received savolitinib orally. The primary endpoint was objective response rate (ORR) by independent review committee in the pivotal phase. In total, 110 patients were enrolled and received savolitinib, including 45 in the exploratory phase and 65 in the pivotal phase. Independent review committee-assessed ORR was 32.3% (95% confidence interval 21.2–45.1%) in the pivotal phase, which met the predefined efficacy threshold (lower limit of 95% confidence interval of ORR ≥15%). Among all patients enrolled (n = 110), grade ≥3 treatment-related adverse events were reported in 38 patients (34.5%); one (0.9%) treatment-related death occurred. Savolitinib monotherapy showed encouraging antitumor activities and a tolerable safety profile in heavily treated, later-line METamp G/GEJ cancers, supporting further investigation in randomized controlled trials. ClinicalTrials.gov identifier: NCT04923932.